BioSpace News Archive

Istari Oncology, Inc. today announced that Jamie Iudica has joined as Chief Manufacturing Officer (CMO).

MannKind Corporation announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the Lytham Partners Summer 2021 Investor Conference on Monday, June 14, 2021 at 11:45 AM (ET).

Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.

Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Company’s senior management will participate in the following virtual investor conference in June 2021: Access China Biotech 2021 Digital (J une 9-1 4 , 2021) The Acces

Oscor receives CE Mark, FDA, and Health Canada clearance on its Breezeway II next generation transseptal access delivery system.

U.S. FDA Approves PREVNAR 20 ™ , Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older.

Antengene’s Partner, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), announced updated data of eltanexor for the treatment of patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that, due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm commitment basis 1,400,000 shares of common stock of the Company, at a price to the public of $22.62 per share, representing a 5% discount to the closing price per share.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today introduced three StarBright Dyes designed for flow cytometry applications.